News
In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...
StockStory.org on MSN2d
Why Moderna (MRNA) Stock Is Falling TodayShares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...
The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 ...
Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease ...
Fresh off of the heels of a shakeup at the CDC over vaccine recommendations, many Americans still question the necessity and ...
Cambridge: Moderna has received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics ...
Moderna’s Covid vaccine for children has been given full FDA approval, making it the first such shot for kids in the U.S. that will no longer be administered under an emergency use authorization.
Yet only small percentages of patients with new diagnoses sought follow-up care, started or completed treatment, or attained ...
The full approval of Spikevax covers children aged six months through 11 years who are at increased risk for severe COVID-19, transitioning the vaccine from emergency use to full licensure.
6d
Zacks Investment Research on MSNMRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric PatientsModerna MRNA announced that the FDA has approved its supplemental biologics license application seeking approval for COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results